Morus Alba leaf extract affects metabolic profiles, biomarkers inflammation and oxidative stress in patients with type 2 diabetes mellitus: A double-blind clinical trial

Abstract

Morus Alba extract, despite its special properties, has been less studied in terms of its effects on metabolic profiles in patients with type 2 diabetes mellitus (T2DM). This study was carried out to determine the effects of Morus Alba extract, known as white mulberry, on liver enzymes, biomarkers of inflammation and oxidative stress, insulin metabolism and lipid profiles in patients with T2DM. The current randomized, double-blind, placebo-controlled trial was conducted among 60 patients with T2DM. Subjects were randomly divided into 2 groups to receive either Morus Alba extract (300mg) (n=30) or placebo (n=30) twice a day. Fasting blood samples were collected at the baseline and 12 weeks after intervention to quantify related markers. Morus Alba extract intake significantly decreased insulin (P=0.026) and malondialdehyde (MDA) (P<0.001), and significantly increased HDL-cholesterol concentrations (P=0.001) compared with the placebo. However, Morus Alba extract intake did not affect other metabolic profiles. The results of this study shown that the 12-week administration of Morus Alba extract among subjects with T2DM had beneficial effects on HDL-cholesterol, insulin and MDA levels, but did not affect other metabolic profiles. The present study was registered in the Iranian website for clinical trials as http://www.irct.ir: IRCT2016081312438N21.